skip to Main Content

VELscope Vx® Approved for Use by AppleWhite Dental Partners

  • February 18, 2013
  • News Releases

BURNABY, British Columbia – March 13, 2013 – LED Medical Diagnostics Inc. (“LED Medical”, “the Company”), announced today that its VELscope Vxx® enhanced early detection system has just been approved for use by AppleWhite Dental Partners. The VELscope Vxx® is exclusively distributed in the U.S. and Canada by Henry Schein, Inc.

“We are very pleased that the VELscope Vxx® has received the approval of yet another demanding and respected group dental practice,” said Peter Whitehead, founder and CEO of LED Dental Inc. and its parent company, LED Medical Diagnostics Inc. “AppleWhite Dental Partners takes great pains to select only the finest technologies for its practices and their patients, and it is very gratifying to have them approve our VELscope Vxx®.”

LED Dental Inc. introduced the first generation of VELscopex®’s fluorescence visualization technology about five years ago in response to the fact that oral cancer was one of the few types of cancer that had not experienced a significant decline in mortality over the previous several decades. VELscopex® technology gives dental practitioners an adjunctive visualization aid that should be used together with, and after, a traditional intra-and extra-oral head and neck exam in hopes of detecting oral lesions that might otherwise have been overlooked.

“Our mission is to create a partnership with our dentists that allow them to practice innovative dentistry and provide an outstanding patient experience,” said Dr. Thomas McCoy, CEO of AppleWhite Dental Partners. “Adding the state-of-the-art VELscope Vxx® enhances the ability of our dentists to discover oral cancer and other oral disease in early stages, and in a way that is completely non-invasive for their patients.”

The National Cancer Institute’s SEER website indicates that oral cancer is most often detected in late stages, when the 5-year survival rate is less than 50%. When detected early, however, the 5-year survival rate leaps to approximately 82%. Because the VELscope Vxx® is so sensitive to oral mucosal changes, it can help increase the odds that cancer will be detected in early and even precancerous stages.

“In fact,” said Mr. Whitehead, “VELscopx® technology increases the likelihood of detecting all types of oral disease at earlier stages, which is good news for the patient as well as the practice.”

Since the launch of the first generation model, over 10,000 VELscopex® devices have been purchased by dental practices globally. It is estimated that these devices have been used to conduct over 10 million oral cancer exams during that time, easily making the VELscopex® the world’s number one adjunctive oral cancer screening technology.

The VELscope Vxx®, the latest generation of the technology, is the first to offer cordless convenience as well as an optional digital camera and customized bracket that make it easy for dentists to photo-document suspicious lesions that are referred to specialists for surgical biopsy.

“We have considered all available options,” said Dr. Mark Mosier, Director of Dentistry for AppleWhite Dental Partners, “and we are confident that the VELscope Vxx® offers the most effective, most convenient and most economical solution for both our practices and their patients.”

AppleWhite Dental Partners provides an array of services to 17 participating dental practices in Iowa, Illinois and Minnesota. By providing business support, professional mentoring, and administrative and consulting services, AppleWhite Dental Partners allows its participating dentists to devote their time to caring for patients, continuing education, and honing clinical skill.

About LED Medical Diagnostics Inc.

Founded in 2003, LED Medical Diagnostics Inc., is a fast-growing public company offering effective early-stage oral cancer detection technologies in 23 countries worldwide. The company makes the VELscope Vxx®, a powerful tool for detecting early stage oral cancer that is approved by the FDA, Health Canada and European regulators. The company is headquartered in Burnaby British Columbia, Canada. For more information please call +1 (604) 434-4614, or visit

About the VELscope Vxx®

The VELscope Vxx® is a powerful FDA-approved tool used to screen for oral cancer. It saves lives by helping detect early stage oral cancer and pre-cancer and other abnormalities in the mouth such as viral, fungal and bacterial infections. The VELscope Vxx® is exclusively distributed worldwide through a partnership with Henry Schein, the world’s largest dental distribution company. For more information please call +1 (604) 434-4614, or visit